This is a randomized, open-label, phase II study evaluating first-line treatment for advanced gallbladder cancer. It aims to assess the efficacy, safety, pharmacokinetics, and immunogenicity of the ZG005 in Combination with gemcitabine and cisplatin as first-line therapy in Participants with advanced gallbladder cancer.
Fully understand the study and voluntarily sign the informed consent form.
Subjects with a histopathological or cytologically diagnosis of Gallbladder cancer.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
Life expectancy of at least 3 months.
Participants were deemed unsuitable for participating in the study by the investigator for any reasons.